These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23604754)

  • 1. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
    Taylor J
    Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754
    [No Abstract]   [Full Text] [Related]  

  • 2. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 4. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 6. With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes.
    Durrington PN
    Evid Based Med; 2015 Feb; 20(1):12. PubMed ID: 25249694
    [No Abstract]   [Full Text] [Related]  

  • 7. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
    Keene D; Price C; Shun-Shin MJ; Francis DP
    BMJ; 2014 Jul; 349():g4379. PubMed ID: 25038074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 10. Not so "good" cholesterol.
    Kritharides L
    BMJ; 2014 Jul; 349():g4664. PubMed ID: 25038076
    [No Abstract]   [Full Text] [Related]  

  • 11. High-density lipoprotein cholesterol raising: does it matter?
    Schofield JD; France M; Ammori B; Liu Y; Soran H
    Curr Opin Cardiol; 2013 Jul; 28(4):464-74. PubMed ID: 23736820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is raising HDL a futile strategy for atheroprotection?
    Joy T; Hegele RA
    Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL-cholesterol levels and cardiovascular risk: acCETPing the context.
    Lange RA; Lindsey ML
    Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471
    [No Abstract]   [Full Text] [Related]  

  • 14. High-density lipoprotein subfractions--what the clinicians need to know.
    Pirillo A; Norata GD; Catapano AL
    Cardiology; 2013; 124(2):116-25. PubMed ID: 23428644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL- cholesterol: a nut too hard to crack?
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352
    [No Abstract]   [Full Text] [Related]  

  • 16. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Illuminating HDL--is it still a viable therapeutic target?
    Rader DJ
    N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.
    Harv Heart Lett; 2007 Mar; 17(7):1-2. PubMed ID: 17378073
    [No Abstract]   [Full Text] [Related]  

  • 20. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.